Edwards Lifesciences on April 23 reported that its largest business, transcatheter aortic valve replacement (TAVR), ...

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

Edwards Lifesciences Corp., Orange County’s most valuable publicly traded medical device maker, reported third quarter sales that signaled its biggest unit might be returning to prior sales growth ...

Fri, February 6, 2026 at 1:15 PM UTC Edwards delivered $1.55 billion in Q3 2025 revenue, beating estimates by $50 million. The company's TAVR franchise continues dominating a market Edwards helped ...

Citi analyst Joanne Wuensch keeps a Buy rating on Edwards Lifesciences (EW) with an $81 price target after the company presented its EARLY TAVR clinical data, saying it came in better than expected ...

Edwards Lifesciences Corporation (NYSE:EW) shares are trading higher on Thursday. Stifel analyst Rick Wise upgraded Edwards from Hold to Buy, raising the price forecast to $90 from $75. Wise suggests ...

Over the last two decades, Edwards Lifesciences has demonstrated that it knows how to maintain leadership through innovation of tissue heart valves. Edwards remains the dominant force in surgical ...

IRVINE, Calif.--(BUSINESS WIRE)--Edwards Lifesciences (NYSE: EW) announced today that the U.S. Food and Drug Administration (FDA) has approved its transcatheter aortic valve replacement (TAVR) therapy ...

Edwards Lifesciences recently announced it would report its first-quarter 2026 results on April 23, with early commentary ...